Results 91 to 100 of about 4,942 (259)

NIR II‐Guided Photoactivatable Silencing Polyplex Boosts Cancer Immunotherapy

Exploration, Volume 5, Issue 5, October 2025.
Due to limitation of penetration therapy with first and second‐generation photodynamic therapy (PDT) photosensitizers, an NIR II‐guided photoactivatable complex was proposed via the self‐assembly of the photosensitive polymer PTSQ and the electrostatic adsorption of siPD‐L1 to enhance cancer immunotherapy.
Yuquan Zhang, Jie Wang, Tian Zhang, Dongsheng Tang, Haiyin Yang, Shuai Guo, Yuchuan Fan, Caixia Sun, Haihua Xiao, Yuanyu Huang, Yuhua Weng   +10 more
wiley   +1 more source

A Case Study of Model‐Informed Drug Development of a Novel PCSK9 Antisense Oligonucleotide. Part 2: Phase 2 to Phase 3

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 10, Page 1556-1561, October 2025.
ABSTRACT In this second part of a case study on the practical use of model‐informed drug development (MIDD), we describe the clinical development of AZD8233, a novel proprotein convertase subtilisin/kexin type 9 (PCSK9) antisense oligonucleotide, from phase 2b to the start of phase 3.
Jane Knöchel, Catarina Nilsson, Björn Carlsson, Alexis Hofherr, Per Johanson, Tina Rydén‐Bergsten, Bengt Hamrén, Dinko Rekić   +7 more
wiley   +1 more source

Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension

, 2023
IntroductionHypertension is the main global risk factor for cardiovascular disease. Despite this, less than half of treated hypertensive patients are controlled.
Addison, Melisande L, Ranasinghe, Priyanga, Webb, David J   +2 more
core   +3 more sources

Effect of Statins and PCSK9 Inhibition on Metabolic Dysfunction–Associated Steatotic Liver Disease

Journal of Digestive Diseases, Volume 26, Issue 9-10, Page 392-397, September-October 2025.
Statins reduce low‐density lipoprotein‐cholesterol (LDL‐C) production and reduce cardiovascular risk and hepatic steatosis in metabolic dysfunction‐associated steatotic liver disease (MASLD), but they have no significant effect on steatohepatitis and/or fibrosis.
Eleni Theocharidou, Thomas Gossios
wiley   +1 more source

Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database

Pharmaceuticals
Introduction: The discovery of serine protease proprotein convertase subtilisin-kexin type 9 (PCSK9) has revolutionized pharmacological lipid-lowering treatments.
Giuseppe Cicala, Michelangelo Rottura, Viviana Maria Gianguzzo, Federica Cristiano, Selene Francesca Anna Drago, Giovanni Pallio, Natasha Irrera, Egidio Imbalzano, Edoardo Spina, Vincenzo Arcoraci   +9 more
doaj   +1 more source

Inclisiran reduces expression of Toll-like receptor-4 on circulating monocytes [PDF]

, 2023
J Bernhard, K Engelberger, Lukas Galli, Patrick Haider, K Ungersbaeck, Christian Hengstenberg, Walter S. Speidl, Konstantin A. Krychtiuk   +7 more
openalex   +1 more source

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

Diabetes, Obesity and Metabolism, Volume 27, Issue S8, Page 34-46, September 2025.
Abstract Lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Despite robust evidence from epidemiological and genetic studies, Lp(a) remains underrecognised in clinical practice due to challenges in measurement, lack of guideline familiarity ...
Alexander C. Razavi, Harpreet S. Bhatia, Roger S. Blumenthal, Michael D. Shapiro, Anurag Mehta   +4 more
wiley   +1 more source

Inclisiran: new era of lipid-lowering therapy? [PDF]

, 2023
Jan Beneš
openalex   +1 more source

Update: Enzymatische Synthese für industrielle Anwendungen

Angewandte Chemie, Volume 137, Issue 27, July 1, 2025.
Die Biokatalyse hat sich zu einer nachhaltigen und wettbewerbsfähigen Alternative zur herkömmlichen chemischen Synthese entwickelt und ermöglicht die enzymbasierte Herstellung nicht nur von chemischen Grundstoffen, sondern auch von (nicht natürlichen) Aminosäuren, (seltenen) Zuckern und synthetischen Nukleotiden.
Thomas Bayer, Shuke Wu, Radka Snajdrova, Kai Baldenius, Uwe T. Bornscheuer   +4 more
wiley   +1 more source

An Update: Enzymatic Synthesis for Industrial Applications

Angewandte Chemie International Edition, Volume 64, Issue 27, July 1, 2025.
Biocatalysis has become a sustainable and cost‐competitive alternative to established chemical synthesis, enabling the enzyme‐based production of not only commodity chemicals but (non‐natural) amino acids, (rare) sugars, as well as synthetic nucleotides.
Thomas Bayer, Shuke Wu, Radka Snajdrova, Kai Baldenius, Uwe T. Bornscheuer   +4 more
wiley   +1 more source